TAGRAXOFUSP is a novel targeted therapy directed to the IL-3 receptor α (CD123), a target present on a wide range of malignancies including Blastic Plasmacytoid Dendritic Nell Neoplasm (BPDCN). It comprises human IL-3 recombinantly fused to a truncated diphtheria toxin (DT) payload engineered such that IL-3 replaces the native DT receptor-binding domain. The IL-3 domain of TAGRAXOFUSP directs the cytotoxic DT payload to cells expressing CD123. Upon internalization, TAGRAXOFUSP irreversibly inhibits protein synthesis and induces apoptosis of the target cell.
TAGRAXOFUSP was approved by the U.S. FDA in 2018 for the treatment of adult and pediatric patients, 2 years or older, with BPDCN.
Important Safety Information
 |
Breakthrough Therapy Designation and Orphan Drug Designation
|
In Europe, on January 2021 TAGRAXOFUSP was approved by the EMA as monotherapy for the first-line treatment of adult patients with BPDCN.
Important Safety Information
 |
Orphan Drug Designation
|
MECHANISM OF ACTION